Brought to you by 
Bristol to produce antibodies using Vical’s platform
19 Aug 2022
Executive Summary
Bristol-Myers Squibb Co. has received nonexclusive global rights to DNA drug delivery company Vical Inc.’s DNA immunization technology to produce antibodies for human therapeutic use.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Liposomes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bristol to produce antibodies using Vical’s platform
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice